Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease
affecting multiple organ systems that runs an unpredictable course and may present with a …

Objective This extension study of the Phase III, randomized, placebo-controlled Belimumab
International SLE Study (BLISS)-52 and BLISS-76 studies allowed non-US patients with SLE …

Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits the
binding of soluble B lymphocyte stimulator to B cells and hence prevents the survival and …

There have been many advances in the diagnosis and therapeutic management of systemic
lupus erythematosus (SLE) over the past decades. Following more than eleven centuries of …

OBSErve Germany was the first observational study of belimumab as add-on treatment for
systemic lupus erythematosus (SLE) in routine clinical care in Germany, retrospectively …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease which affects the
majority of organs and systems. Traditional therapies do not lead to complete remission of …

In this review, the results of recent and ongoing clinical trials in patients with SLE are
discussed. After many unsuccessful trials in the past decade, belimumab was the first …

Belimumab is the only approved biological agent for the treatment of systemic lupus
erythematosus (SLE). It is a fully humanized IgG1γ monoclonal antibody directed against …

Objective We undertook this US multicenter continuation study (GlaxoSmithKline study BEL
112233; ClinicalTrials. gov identifier: NCT 00724867) to assess long‐term safety and …

We investigated whether belimumab treatment impacts on levels of autoantibodies and
cytokines of interest in systemic lupus erythematosus (SLE). Longitudinally collected serum …